Tolerability of 532 nm Laser Treatment of Port Wine Stains
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT05841628
- Status
- Recruiting
Conditions
- Port-Wine Stain
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- 532 nm laser treatment — DEVICEThe port wine birthmark will be treated with the DermaV 532 nm laser.
Study Details
The goal of this study is to learn about treatment of port wine birthmarks treated with an FDA-approved 532 nm laser. The main questions it aims to answer are: * How well are the treatments tolerated? * Are there differences in tolerability of the treatment when a single high fluence laser pulse is used (the standard treatment) versus using multiple low fluence pulses? * Are there differences in results when using a single high fluence pulse versus multiple low fluence pulses? type of study: Clinical Trial Participants will undergo 3 monthly laser treatments with the 532 nm DermaV laser. Part of their birthmark will be treated with the standard single-pulse high fluence approach, and other parts will be treated with the multiple-pulse low fluence approach.
Key Dates
- Start date
- May 1, 2023
- Status verified
- Nov 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Port wine stainThe port wine stain will be treated with the DermaV laser. Within the single port wine stain, one area will be treated with standard settings (single pulse high fluence). Four other areas will be treated with multi-pulse low fluence settings. A sixth area will be an untreated control.
Primary Outcome Measure
Degree of improvement [ Time Frame: 6 months ]
Central Contacts
- Cemre Turk, MD6175133337
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Wellman Center for Photomedicine, Harvard Medical School | Boston | Massachusetts | 02114 | Beverly Dammin 617-726-3008 |
Find similar trials in Boston, MA
Related Studies
- A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDTPHASE2 · Recruiting · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Irvine, California